Int J Med Sci 2022; 19(10):1603-1614. doi:10.7150/ijms.74575 This issue
1. Department of Anesthesiology & Perioperative Medicine, Xi'an People's Hospital (Xi'an Fourth Hospital), Xi'an, Shaanxi 710100, China.
2. Department of Stomatology, Xi'an People's Hospital (Xi'an Fourth Hospital), Xi'an, Shaanxi 710100, China.
* These authors contribute equally to this review and should be considered co-first authors. * These authors should be considered corresponding authors.
Periodontitis is a chronic inflammatory disease that affects tooth-supporting tissues and even leads to tooth loss. NLRP3 inflammasomes play a critical role in periodontitis pathogenesis. Aberrant activation or overexpression of NLRP3 inflammasomes in cellular players, including osteoclasts, osteoblasts, periodontal ligament fibroblasts, and leukocytes often contributes to cellular dysfunction and environment abnormality, thus resulting in the disorganization of ligament and alveolar bone. In this review, we mainly focus on the negative regulation of NLRP3 inflammasome in periodontitis and highlight the importance of NLRP3 inflammasome as a candidate therapeutic target in periodontitis treatment. Then we elucidate the development status of NLRP3 inflammasome inhibitors and show their application potential for treating periodontitis. In summary, this review reveals the recent progress and perspectives of NLRP3 inflammasome and the therapeutic potential of NLRP3 inflammasome inhibitors in periodontitis.
Keywords: Periodontitis, NLPR3 Inflammasome, Periodontal Ligament Cell, Osteoclast, Osteoblast, Leukocyte